Correction of insulin resistance syndrome does not cause normalisation of hyperferritinaemia;Impact de la correction des facteurs de risque du syndrome métabolique sur l'hépatosidérose dysmétabolique

Gastroenterologie Clinique et Biologique

Volumn 27, Issue 12, 2003, Pages 1079-1083

  Roblin, Xavier ^a   Phelip, Jean Marc ^a   Hilleret, Marie Noëlle ^a   Heluwaert, Frederic ^a   Bonaz, Bruno ^a   Zarski, Jean Pierre ^a  

^a HÔPITAL MICHALLON   (France)

Author keywords

[No Author keywords available]

Indexed keywords

FERRITIN; IRON;

ADULT; ARTICLE; DISEASE COURSE; FEMALE; FERRITIN BLOOD LEVEL; HUMAN; HYPERFERRITINEMIA; INSULIN RESISTANCE; IRON OVERLOAD; LIVER HEMOSIDEROSIS; MAJOR CLINICAL STUDY; MALE; PATHOPHYSIOLOGY;

ADULT; AGED; FEMALE; HUMANS; IRON OVERLOAD; LIVER; MAGNETIC RESONANCE IMAGING; METABOLIC SYNDROME X; MIDDLE AGED; TREATMENT OUTCOME;

EID: 1642516957     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (18)

1. Moirand R, Mortaji A, Loréal O, Paillard F, Brissot P, Deugnier Y. Liver iron overload with normal transferrin saturation: a new syndrome. Lancet 1997;349:95-7.
2. Mendler M, Turlin B, Moirand R, Jouanolle A, Sapey T, Guyader D, et al. Insulin resistance - associated hepatic iron overload. Gastroenterology 1999;117:1-10.
3. George DK, Goldwurm S, MacDonald GA, Cowley LL, Walko NI, Wood PJ, et al. Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterotogy 1998;114:311-8.
4. Blanc JF, De Lédinghen V, Trimoulet P, Le Buil B, Bernard PH, Sarie J, et al. Premalign lesions and hepatocellular carcinoma in a non-cirrhotic alcoholic patient with iron overload and normal transferrin saturation. J Hepatol 1999;30:325-9.
5. Deugnier Y, Turlin B, Loréal O. Iron and neoplasia. J Hepatol 1998;28:21-5.
6. Salonen J, Nyyssönen K, Korpela H, Tuomilehto J, Seppänen R, Salonen R. High stored iron levels are associated with excess risk of myocardal infarction in Eastern Finnish men. Circulation 1992;86:803-1.
7. Guillygomarc'h A, Moirand R, Mendler MH, Brissot P, Deugnier Y. Hepatosidérose dysmétabolique: tolérance et efficacité des phlébotomies (résumé). Gastroenterol Clin Biol 2000, 2bis A69.
8. Guillygomarc'h A, Mendler MH, Moirand R, Lainé F. Quentin V, David V, et al. Venesection therapy of insulin resistance-associated hepatic iron overload. J Hepatol 2001;35:344-9.
9. Association AD. Consensus development conference on insulin resistance. Diabetes Care 1998;21:310-4.
10. Gore RM. Diffuse liver disease. In: Gore RM, Levine MS, Laufer I, eds. Textbook of gastronitestinal radiology. Philadelphia: Saunders 1994:1968-2017.
11. Deugnier Y, Loréal O. Iron as a carcinogen. In: Barton J, Edwards C, editors. Haemochromatosis. Cambridge: Cambridge University Press 2000. pp. 239-49.
12. De Valk B, Marx J. Iron, atherosclerosis, and ischemic heart disease. Arch Intern Med 1999;159:1542-8.
13. Kallo A, Lakatos I, Szijarto L. Donohue's syndrome. J Ped 1965;66:372.
14. Hunter S, Garvey T. Insulin action and insulin resistance: diseases involving defects in insulin receptors, signal transduction, and the glucose transport effector system. Am J Med 1998;105:372-45.
15. Fernandez-Real J, Ricart-Engel W, Arroyo E, Balança R, Casamitjana-Abella R, Cabrero D, Fernandez-Castaner M, Soler J. Serum ferritin as a component of the insulin resistance syndrome. Diabetes Care 1998;21:62-8.
16. Tanner L, Lienhard G. Insulin elicits a redristribution of transferrin receptors in 3T3-L1 adipocytes through an increase in the rate constant for receptor externalization. J Biol Chem 1987;262:8975-80.
17. Palmer M, Schaffner F. Effect of weight reduction on hepatic abnormalities in overweight patients. Gastroenterology 1990;99:1408-13.
18. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol 1997:27:103-7.